SnagRx vs Gala: Pricing, pharmacies, shipping and clinician care
SnagRx vs Gala compares two direct-pay telehealth platforms that offer compounded semaglutide and tirzepatide. Early verdict: SnagRx is the clearer low-cost option on an annual plan, while Gala emphasizes included provider check-ins and a promotional flat price.
See SnagRx pricing from $69/mo
How they stack up at a glance
| Criteria | SnagRx | Gala |
|---|---|---|
| Starting price shown | From $69/month semaglutide on 12-month plan; month-to-month $99 | Compounded semaglutide noted from $249/mo; page shows a $220 promotion but base price not visible in readable text |
| Price model | Price locked flat at every dose and at renewal on annual plan | One flat all-inclusive price claimed; same price at every dose claimed |
| Clinician access and care | Telemed clinician review via OpenLoop Health; clinician review typically within 5 hours | Provider visit and prescription included; provider check-ins and dose monitoring included |
| Pharmacy and shipping | Names its four US 503A partner pharmacies; next-day UPS/FedEx shipping | Free 2-day shipping; pharmacy partners not named in captured text |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
Price and commitment: locked annual rate versus promotional flat price
Pricing is the clearest divergence. SnagRx advertises compounded semaglutide from $69/month and tirzepatide from $119/month as the 12-month plan rates, and month-to-month prices are $99 and $149. SnagRx states the annual plan rate is locked flat at every dose and at renewal. Gala markets a flat all-inclusive price with a $220 promotion and advertises compounded semaglutide from $249/month in page text, but the page capture did not expose a clear base dollar price in readable text. If transparent annual pricing or a locked-in rate on escalation matters, the available evidence points to SnagRx on the annual plan.
Clinician access, monitoring and ongoing care
Both providers include the provider visit and prescription. SnagRx uses a clinician network called OpenLoop Health, states clinicians typically review intake within five hours and covers 48 states. Gala highlights provider check-ins and dose monitoring included as part of its service. SnagRx explicitly notes no coaching or nutrition programming of any kind, while Gala’s captured materials emphasize check-ins and ongoing care. Choose based on whether you prioritize fast clinician review and named clinicians or included monitoring and check-ins.
Pharmacies, fulfillment and shipping speed
SnagRx names its four US 503A partner pharmacies and promises next-day UPS/FedEx shipping in temperature-controlled packaging. Gala promises free two-day shipping but the captured page text does not list named pharmacies. If knowing the compounding pharmacy partners is important, SnagRx supplies that detail in its captured materials.
Regulatory and product type considerations
Both platforms offer compounded semaglutide and tirzepatide, and both capture the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. SnagRx further states compounded medications are produced in FDA-regulated facilities and encourages prospective users to speak with their provider about specific risks. Gala also states that compounded medications are not FDA-approved in the captured text.
See Gala eligibility and pricing
Marketing claims and transparency
SnagRx highlights bottom-of-market annual pricing, a price lock at every dose, named pharmacies, a named clinician network and a stated LegitScript certification. SnagRx also notes a full refund if the prescription is declined and a 6-month weight-loss guarantee with terms applied. Gala uses promotional testimonials and a $220 discount offer in page text and claims the same price at every dose, but the captured content shows the base price was not visible in readable page text. Testimonials on Gala are identified in the capture as provider marketing.
Claim Gala promotion and check details
Final comparison and quick recap
SnagRx vs Gala splits on transparency and the shape of included care. SnagRx is explicit about 12-month plan pricing from $69/month, names its 503A pharmacies and cites a rapid clinician review through OpenLoop Health. Gala emphasizes provider check-ins and a single flat all-inclusive price with a promotion, but the captured page did not show a clear base price in readable text or named pharmacies.
Choose one if…
Choose SnagRx if you want an annual plan with a starting advertised rate of $69/month for compounded semaglutide, a stated price lock at every dose, named US 503A partner pharmacies and a clinician network that typically reviews intake within five hours.
Choose Gala if you prefer a platform that highlights included provider check-ins and a single flat all-inclusive price with a promotional discount, and you will confirm base price, renewal terms and state availability before enrolling.